Inhibrx Biosciences, Inc.

INBX · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders23.1%

Institutions91.0%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$1.30M	$200000	$1.80M	$2.19M	$7.23M	$12.89M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$135.03M	-$331.45M	-$219.22M	-$129.12M	-$76.56M	-$67.44M
Operating income as a percentage of revenue.	-10386.5%	-165724.0%	-12178.9%	-5890.4%	-1058.8%	-523.3%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$140.06M	$1.69B	-$241.36M	-$145.23M	-$81.77M	-$76.12M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-9.00	$114.00	$-5.00	$-3.00	$-2.15	$-3.01
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-9.00	$112.00	$-5.00	$-3.00	$-2.15	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$124.20M	$152.60M	$277.90M	$273.90M	$131.30M	$128.70M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$146.48M	$180.77M	$307.89M	$290.88M	$150.45M	$143.74M
All of the company's interest-bearing borrowings, short and long term combined.	$100.56M	$0	–	–	–	$0
Everything the company owes — debt, unpaid bills, and other obligations.	$138.49M	$47.18M	$264.39M	$232.82M	$98.07M	$68.27M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$7.99M	$133.58M	$43.50M	$58.06M	$52.38M	$75.47M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$129.79M	-$194.41M	-$193.31M	-$115.30M	-$80.32M	-$47.97M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$31000	$2.60M	$4.59M	$686000	$864000	$1.36M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$129.82M	-$197.01M	-$197.90M	-$115.99M	-$81.19M	-$49.33M

	You	Peer avg
Revenue Growth	–	+29.6%
ROE	-1773.6%	-116.0%

Inhibrx Biosciences, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison